EA200800880A1 - Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции - Google Patents
Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функцииInfo
- Publication number
- EA200800880A1 EA200800880A1 EA200800880A EA200800880A EA200800880A1 EA 200800880 A1 EA200800880 A1 EA 200800880A1 EA 200800880 A EA200800880 A EA 200800880A EA 200800880 A EA200800880 A EA 200800880A EA 200800880 A1 EA200800880 A1 EA 200800880A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rosiglitazone
- pharmaceutically acceptable
- acceptable salt
- dropseen
- intended
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004586 rosiglitazone Drugs 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 229960003530 donepezil Drugs 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71935305P | 2005-09-22 | 2005-09-22 | |
| US72737705P | 2005-10-17 | 2005-10-17 | |
| PCT/US2006/036597 WO2007038112A2 (en) | 2005-09-22 | 2006-09-20 | Combination of rosiglitazone and donepezil for improvement of cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200800880A1 true EA200800880A1 (ru) | 2009-02-27 |
Family
ID=37876831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800880A EA200800880A1 (ru) | 2005-09-22 | 2006-09-20 | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции |
| EA200800879A EA200800879A1 (ru) | 2005-09-22 | 2006-09-20 | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800879A EA200800879A1 (ru) | 2005-09-22 | 2006-09-20 | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080226719A1 (https=) |
| EP (2) | EP1926488A2 (https=) |
| JP (2) | JP2009508960A (https=) |
| KR (2) | KR20080056731A (https=) |
| AR (2) | AR055649A1 (https=) |
| AU (2) | AU2006295010A1 (https=) |
| BR (2) | BRPI0616100A2 (https=) |
| CA (2) | CA2623210A1 (https=) |
| CR (2) | CR9849A (https=) |
| EA (2) | EA200800880A1 (https=) |
| IL (2) | IL190217A0 (https=) |
| MA (2) | MA29871B1 (https=) |
| NO (2) | NO20081847L (https=) |
| PE (2) | PE20070976A1 (https=) |
| TW (2) | TW200803896A (https=) |
| WO (2) | WO2007038115A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| ME01898B (me) | 2008-08-12 | 2014-12-20 | Zinfandel Pharmaceuticals Inc | Metoda za identifikaciju faktora rizika od alchajmerove bolesti |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| WO2010150261A1 (en) * | 2009-06-25 | 2010-12-29 | Alcobra Ltd. | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| WO2012053016A1 (en) * | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| BR112013017444A2 (pt) * | 2011-01-10 | 2016-09-27 | Zinfandel Pharmaceuticals Inc | método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente |
| AU2012205798B2 (en) | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
| AU2012326976B2 (en) | 2011-10-21 | 2017-08-17 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| CA2853100A1 (en) * | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| WO2014171542A1 (ja) * | 2013-04-19 | 2014-10-23 | 武田薬品工業株式会社 | 放出制御製剤 |
| US10391079B2 (en) * | 2016-07-26 | 2019-08-27 | Ausio Pharmaceuticals, Llc | Methods of diagnosing and treating Alzheimer's disease with S-equol |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR102224917B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3265577B2 (ja) * | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白ｅの４型イソ型の測定法 |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| AU2192000A (en) * | 1998-12-17 | 2000-07-03 | Mindset Biopharmaceuticals (Usa) Inc. | Increasing brain glucose utilization |
| WO2005074917A1 (en) * | 2004-01-30 | 2005-08-18 | Axonyx, Inc. | Methods for treatment of complications of diabetes |
-
2006
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en not_active Ceased
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en not_active Ceased
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
-
2008
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007038112A2 (en) | 2007-04-05 |
| US20080262047A1 (en) | 2008-10-23 |
| US20080226719A1 (en) | 2008-09-18 |
| AU2006295010A1 (en) | 2007-04-05 |
| AR056527A1 (es) | 2007-10-10 |
| EA200800879A1 (ru) | 2008-10-30 |
| EP1940403A2 (en) | 2008-07-09 |
| IL190217A0 (en) | 2008-11-03 |
| WO2007038115A3 (en) | 2007-12-13 |
| KR20080056731A (ko) | 2008-06-23 |
| KR20080058413A (ko) | 2008-06-25 |
| CR9848A (es) | 2008-06-18 |
| AR055649A1 (es) | 2007-08-29 |
| MA29872B1 (fr) | 2008-10-03 |
| EP1926488A2 (en) | 2008-06-04 |
| CR9849A (es) | 2008-05-21 |
| JP2009508959A (ja) | 2009-03-05 |
| AU2006295007A1 (en) | 2007-04-05 |
| PE20070618A1 (es) | 2007-07-04 |
| CA2623210A1 (en) | 2007-04-05 |
| PE20070976A1 (es) | 2007-12-05 |
| WO2007038112A3 (en) | 2007-12-06 |
| NO20081847L (no) | 2008-06-18 |
| TW200803896A (en) | 2008-01-16 |
| JP2009508960A (ja) | 2009-03-05 |
| MA29871B1 (fr) | 2008-10-03 |
| WO2007038115A2 (en) | 2007-04-05 |
| CA2623204A1 (en) | 2007-04-05 |
| BRPI0616100A2 (pt) | 2011-06-07 |
| IL190224A0 (en) | 2008-11-03 |
| BRPI0616192A2 (pt) | 2011-06-14 |
| NO20081843L (no) | 2008-06-16 |
| TW200803851A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| WO2003103603A3 (en) | Novel formate salt of o-desmethyl-venlafaxine | |
| ATE458753T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
| GB0223040D0 (en) | Therapeutic compounds | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EA200400881A1 (ru) | Азаарилпиперазины | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| SE0104341D0 (sv) | New use | |
| WO2005018545A3 (en) | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
| EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| EA200600866A1 (ru) | Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний | |
| UA83328C2 (ru) | Состав для профилактики заболеваний полости рта | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| DK1492539T3 (da) | Statin-terapi til forögelse af kognitiv funktion |